Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- Top 10 News for 03/23 - 03/27: Kraft/Heinz Mega Food Merger, SanDisk Warns, Biotech Bubblicious
- Intel (INTC) in Talks to Buy Altera Corp (ALTR) - WSJ
- Dow Chemical (DOW) to Separate Chlor-Alkali Unit, Merge it with Olin (OLN)
- UPDATE: BlackBerry (BBRY) Posts Q4 adj.-EPS of 4c
- Unusual 11 Mid-Day Movers 03/27: Higher GBSN, OLN, OXM; Lower OHRP, MOLG, APDN (more...)
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Pioneer Energy Services Corp (PES) to Hold
- Piper Jaffray Upgrades Kirkland's (KIRK) to Overweight
- Finish Line (FINL) Results, Outlook Shows Foot Locker (FL) Is Winning the War, Sterne Agee Says
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!